Trial
NCT05879458
Ritlecitinib in CTCL
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Pfizer
Condition
CTCL
Intervention
Ritlecitinib
Why stopped
No significant improvement in disease as graded by our assessments.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-18